رجوع
نطاق اليوم
KWD 8.88
KWD 9.39
نطاق 52 أسبوعًا
KWD 8.50
KWD 14.87
حجم التداول
97,577
متوسط 50 يوم / 200 يوم
KWD 10.90
/
KWD 11.14
الإغلاق السابق
KWD 8.72
Quick Summary
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (627 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -5.5 | 0.3 |
| P/B | 1.8 | 3.0 |
| ROE % | -44.7 | 3.7 |
| Net Margin % | — | 3.8 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | 0.0 | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 21.67
+134.3%
Low: KWD 18.00
High: KWD 24.00
ربحية السهم المستقبلية
-KWD 2.18
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
-KWD 2.31
-KWD 2.31 – -KWD 2.31
|
17.00M | 1 |
| FY2029 |
-KWD 2.08
-KWD 2.08 – -KWD 2.08
|
0.0 | 1 |
| FY2028 |
-KWD 2.13
-KWD 2.47 – -KWD 1.63
|
0.0 | 5 |
No quarterly estimates available
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 |
Mehra Uneek
Chief Financial Officer
|
grant | 128,330 | — | — |
| Mar 10, 2026 |
Beltran Pedro
Chief Scientific Officer
|
grant | 256,670 | — | — |
| Mar 10, 2026 |
Ben Yong
Chief Med & Dev Officer
|
grant | 256,670 | — | — |
| Jan 1, 2026 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1,114,400 | — | — |
| Dec 10, 2025 |
Wallace Eli M.
Chief Executive Officer
|
sell | 1,114,400 | — | — |
| Oct 10, 2025 |
BridgeBio Pharma LLC
|
other | 784,720 | — | — |
| Oct 2, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1,614,400 | — | — |
| Aug 26, 2025 |
Mehra Uneek
Chief Financial Officer
|
grant | 633,570 | — | — |
| Aug 26, 2025 |
Ben Yong
Chief Med & Dev Officer
|
grant | 357,177 | — | — |
| Aug 26, 2025 |
Tipirneni Praveen P.
|
grant | 52,269 | — | — |
| Aug 26, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 499,731 | — | — |
| Aug 26, 2025 |
Bauer Jake
|
grant | 138,193 | — | — |
| Aug 26, 2025 |
Beltran Pedro
Chief Scientific Officer
|
grant | 357,177 | — | — |
| Aug 26, 2025 |
MCCORMICK FRANK
|
grant | 91,076 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
other | 8,344,252 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
sell | 460,814 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
grant | 10,950,408 | KWD 10.72 | — |
| Aug 11, 2025 |
McKenna Mark C.
|
other | 60,000 | — | — |
| Aug 11, 2025 |
Schmid John P.
|
other | 60,000 | — | — |
| Aug 11, 2025 |
Holman Albert A III
|
other | 60,000 | — | — |
Dividend History
Yield
0.00%
Payout Ratio
0.00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
النقاط الرئيسية
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -114.50M
PEG of 0.00 suggests growth is underpriced
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-44.70%
ROIC-26.43%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
0.01
Current Ratio12.14
Interest Coverage0.00
التقييم
P/E Ratio
-5.52
Forward P/EN/A
P/B Ratio1.80
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -134.04M |
| ROE | -44.70% | ROA | -29.90% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -114.50M |
| ROIC | -26.43% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 12.14 |
| Interest Coverage | 0.00 | ||
| Dividends | |||
| Dividend Yield | 0.00% | Payout Ratio | 0.00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -5.52 | Forward P/E | N/A |
| P/B Ratio | 1.80 | P/S Ratio | N/A |
| PEG Ratio | 0.00 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -15.47% | ||
| Market Cap | 740.30M | Enterprise Value | 369.38M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -134.04M | -74.28M | -64.70M | -3,520.0 | -43,357.0 |
| EPS (Diluted) | -4.30 | 0.46 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -610,000.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating Income | -145.82M | -80.86M | -64.77M | -3,520.0 | -43,357.0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448.38M | 194.42M | 332,894.0 | 144,578.0 | 144,281.0 |
| Total Liabilities | 37.29M | 5.71M | 396,463.0 | 166,455.0 | 162,638.0 |
| Shareholders' Equity | 411.10M | 188.72M | -63,569.0 | -21,877.0 | -18,357.0 |
| Total Debt | 2.77M | 0.0 | 70,095.0 | 43,106.0 | 36,961.0 |
| Cash & Equivalents | 373.69M | 1.70M | 0.0 | 0.0 | 0.0 |
| Current Assets | 425.46M | 1.95M | 0.0 | 0.0 | 0.0 |
| Current Liabilities | 35.04M | 187,515.0 | 396,463.0 | 166,455.0 | 162,638.0 |